Analysis of changes in reporting and diagnosis of pulmonary tuberculosis among children in Liangshan Yi Autonomous Prefecture, Sichuan Province from 2019 to 2021.
10.3760/cma.j.cn112150-20230315-00192
- Author:
Xiao Ran YU
1
;
Shi Jin WANG
2
;
Xue Mei YANG
1
;
Min FANG
3
;
Xi ZENG
1
;
Hui QI
1
;
Wei Wei JIAO
1
;
Lin SUN
1
Author Information
1. Beijing Children's Hospital, Capital Medical University/National Center for Children's Health, Beijing 100045, China.
2. Liangshan Zhou Center for Disease Control and Prevention, Chronic Infectious Disease Prevention and Control Institute, Liangshan 615000, China Chengdu Tianfu New Area Xianghe Community Healthcare Center, Chengdu 610213, China.
3. The No. 1 People's Hospital of Liangshan Yizu Autonomous Prefecture, Liangshan 615000, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Child;
Rifampin/therapeutic use*;
Isoniazid/therapeutic use*;
Tuberculosis, Pulmonary/drug therapy*;
Tuberculosis;
China/epidemiology*
- From:
Chinese Journal of Preventive Medicine
2023;57(8):1153-1159
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To compare the characteristics of children's pulmonary tuberculosis (PTB) cases reported from 2019 to 2021 before and during the implementation of the Action Plan to Stop Tuberculosis. Methods: Based on the reported incidence data and population data of child pulmonary tuberculosis (PTB) notified to the Chinese Center for Disease Control and Prevention (CDC) Tuberculosis Information Management System (TBIMS) from 2019 to 2021, the population information and clinically relevant information in different years were compared. Results: From 2019 to 2021, the reported cases of PTB in children were 363, 664 and 655, respectively. The number of reported cases increased significantly. The median age of the cases in children increased from 10.4 years in 2019 to 11.7 years in 2021 (P=0.005) over a three-year period. The etiological positive rate increased significantly from 11.6% (42/363) in 2019 to 32.2% (211/655) in 2021 (P<0.001). The positive rate of molecular testing increased most significantly, which became the main means of etiological detection and accounted for 16.7% (7/42), 62.0% (57/92) and 75.4% (159/211) of the children with positive etiological results, respectively. The resistance rates of isoniazid and rifampicin were analyzed in children with PTB who underwent drug sensitivity tests. The results showed that the resistance rates of isoniazid and/or rifampicin were 2/9, 3.9% (2/51) and 6.7% (11/163), respectively, with an average of 6.7% (15/223) over three years. The median patients' delay was 27 (12, 49) days in 2019. It was reduced to 19 (10, 37) days in 2020 and 15 (7, 34) days in 2021, both significantly lower than 2019 (P=0.009 and 0.000 2, respectively). Conclusion: From 2019 to 2021, the reported numbers of children with PTB and children with positive etiological results increase significantly in Liangshan Prefecture, while the diagnosis delay of patients significantly reduces.
